

# Angiogenesis Inhibitors and Stimulators: Market Research Report

<https://marketpublishers.com/r/A874EE8DE26EN.html>

Date: April 2012

Pages: 675

Price: US\$ 4,950.00 (Single User License)

ID: A874EE8DE26EN

## Abstracts

This report analyzes the worldwide markets for Angiogenesis Inhibitors and Stimulators in US\$ Million by the following Product Segments: Angiogenesis Inhibitors, and Angiogenesis Stimulators.

Annual estimates and forecasts are provided for the period 2009 through 2017.

Also, a six-year historic analysis is provided for these markets.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia Pacific, Middle East, and Latin America.

The report profiles 69 companies including many key and niche players such as Abbott Laboratories, Adnexus Therapeutics, Inc., Aeterna Zentaris Inc., Amgen, Inc., Angstrom Pharmaceuticals Inc., AstraZeneca Plc, Bayer HealthCare AG, Callisto Pharmaceuticals, Inc., Celgene Corporation, Celltech Group Plc., Cephalon Inc., Eisai Inc., Eli Lilly And Company, ImClone Systems Inc., EntreMed Inc., GenVec Inc., Genzyme Corp., GlaxoSmithKline plc, Merck KGaA, Novartis, OSI Pharmaceuticals, Inc., Eyetech, Inc., Pfizer Inc., Progen Industries, Regeneron Pharmaceuticals, Roche, Genentech Inc., Chugai Pharmaceutical Co.Ltd., Silence Therapeutics, and ThromboGenics Limited.

Market data and analytics are derived from primary and secondary research.

Company profiles are primarily based upon search engine sources in the public domain.

## Contents

### **I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS**

Study Reliability and Reporting Limitations

Disclaimers

Data Interpretation & Reporting Level

Quantitative Techniques & Analytics

Product Definitions and Scope of Study

#### **1. ANGIOGENESIS INHIBITORS**

#### **2. ANGIOGENESIS STIMULATORS**

### **II. EXECUTIVE SUMMARY**

#### **1. MARKET OUTLOOK**

Angiogenesis: In the Spotlight

Angiogenesis: A Preview

#### **2. MARKET OVERVIEW**

Angiogenesis Makes Inroads: A Retrospect

Angiogenesis: Ushering-In a New Era

Angiogenesis: Fact File

Milestones in Research Achieved Over the Years

Anti-Angiogenic Drugs Market – An Overview

Angiogenic Inhibitors Market to Surge

The Long Journey for Anti-Angiogenesis Therapies

Approved Anti-Angiogenesis Drugs in the Market

Select FDA-Approved Anti-Angiogenic Drugs/ Therapeutics In Oncology By Type

Monoclonal Antibody Therapies

Small Molecule Tyrosine Kinase Inhibitors

Inhibitors of mTOR

Other Anti-Angiogenic Agents

Leading Drugs in the Market

Avastin Leads the Fray

**Table 1.** Select Leading Drugs in the Global Anti-Angiogenesis Market: Annual Sales in US\$ Million for Years 2008 & 2009 (includes corresponding Graph/Chart)

Overview of Select Leading Drugs

Avastin

Survival Benefit Conferred by Avastin

Mechanism of Action

General Mode of Delivery

Side Effects Elicited on Administering Avastin

ERBITUX™ (Cetuximab)

Regulatory Approvals

Erbix in Head and Neck Cancer

Glivec/Gleevec (imatinib mesylate)

Herceptin (Trastuzumab)

Sutent (Sunitinib)

Other Regulatory Approvals

Sunitinib in Various Indications

Sunitinib in Renal Cell Carcinoma (RCC)

Sutent in Gastrointestinal Stromal Tumors (GIST)

Cost Related Issues

Tarceva (Erlotinib)

Other Regulatory Approvals

Thalomid® (Thalidomide)

**Table 2.** Thalomid – Percentage Breakdown Based on Relative Oncology Application (includes corresponding Graph/Chart)

Cilengitide

Imiquimod

Angiogenesis Inhibitors – Pipeline Status

Select Anti-Angiogenesis Drugs in Phase III Development

Select Anti-Angiogenesis Drugs in Phase II Development

Select Anti-Angiogenesis Drugs in Phase I Development

Select Approved Indications of Anti-VEGF/VEGFR Drugs

Novel Targets for Anti-Angiogenic Activity

Select Approved HER Receptor-Targeting Drugs

Select Approved m-TOR Inhibitors

Integrins

Select Integrin Targeting Drugs under Development

Angiogenic Inhibitors – By Disease Application

Cancer

Various Types of Cancers Targeted by Angiogenesis Inhibitors in Phase III Clinical Development

Diabetic Retinopathy

Female Reproductive Cycle

Psoriasis

Inflammatory Diseases

**Table 3.** Classification of Anti-Angiogenic Compounds Based on Most Commonly Targeted Indication (includes corresponding Graph/Chart)

Angiogenesis Inhibitors in Eye Related Diseases

Age-Related Macular Degeneration

Wet AMD

Dry AMD

Select Anti-Angiogenic Drugs Approved by FDA for Treatment of Eye Diseases

Angiogenesis Inhibitors in Dermatology

Select Drugs/Therapeutics with Angiogenic Mode of Action Approved by FDA for Dermatology

### 3.MARKET TRENDS

Cancer – The Key Target Indication for Research in Anti-Angiogenesis Drugs

Avastin Continues to Record Robust Growth

New Markets Offer Higher Potential for Herceptin

Increased Use Drives Tarceva's Growth in Developed Markets

Angiogenesis Inhibitors Continue to Dominate RCC Drug Market

Votrient to Lead Renal Cell Carcinoma (RCC) Drug Market

**Table 4.** Leading Drugs in the Global Second Line Advanced Renal Cell Carcinoma Market (2010): Percentage Breakdown by Value Sales for Nexavar, Torisel, Afinitor, Avastin, and Others (includes corresponding Graph/Chart)

Clinical Benefits of Votrient Over Sutent

US FDA Revokes Avastin Approval for Breast Cancer

#### **4.ANGIOGENESIS REPERTOIRE**

An In-depth Insight into Angiogenesis  
Angiogenesis: At a Glance  
Requisites for Angiogenesis  
Endogenous Regulators of Angiogenesis  
Angiogenic Process: Sequence of Events  
Angiogenesis Process in Children  
Angiogenesis Process in Adults  
The Process of Angiogenesis in Thyroid Gland

#### **5.ANGIOGENESIS INHIBITORS**

Angiogenic Inhibitors: Basic Framework  
Natural Inhibitors  
Thrombospondin  
Interferon  
Cryptic Inhibitors  
Other Natural Inhibitors  
Natural Sources for Anti-Angiogenic Action  
Potential Anti-Angiogenic Drugs of Natural Origin  
Angiogenic Inhibitors: On the Verge of Attaining Superior Clinical Efficacy  
Endogenous vs Synthetic Agents  
Angiogenesis Inhibitors: Classification Based on Source of Origin  
Anti-Angiogenic Molecules: Classification Based on Mode of Action  
Broad Overview of Anti-Angiogenic Therapies  
Pre-Requisites for Any Drug to be an Angiogenic Inhibitor  
Specific Therapeutic Strategies of Anti- Angiogenesis Agents  
Inhibiting Angiogenesis In Vivo  
Antiangiogenic Tumor Therapy  
Antivascular Therapy: Adding a New Dimension  
MMPs – Exhibiting Dual Role  
Angiogenesis Inhibitors Vs Standard Chemotherapy  
Comparison Between Cytostatic Antiangiogenesis and Cytotoxic Chemotherapy  
Proteoglycan Mixture: Therapeutic Powerhouse  
Features of VascuStatin  
Angiogenesis Inhibition Versus Cytotoxic Therapy

Relationship Between Copper and Angiogenesis  
Anti-Angiogenesis Action of Pencillamine  
Outline of Steps Involved in Drug Discovery for Angiogenesis  
Drug Delivery: Their Influence on Therapeutics

## **6.PROMOTERS OF ANGIOGENESIS/ ANGIOGENESIS STIMULATORS**

Angiogenesis Stimulators  
Growth Factors  
Angiogenic Stimulators in the Market  
Stimulators Exhibiting Profound Influence on Angiogenesis  
Vascular Endothelial Growth Factor (VEGF)  
VEGF and Their Influence on Diabetes and Diabetic Retinopathy  
Fibroblast Growth Factors (FGFs)  
Basic Fibroblast Growth Factor (bFGF)  
Placental Growth Factor (PIGF)  
Recombinant  $\alpha 4$  Fragment  
Hepatocyte Growth Factor/ Scatter Factor (HGF/SF)  
Angiogenin  
Platelet Derived Endothelial Cell Growth Factor  
Applications of Angiogenic Stimulators vis-à-vis Disease Perspective  
Cardiac Diseases  
Wound Healing and Burns  
Critical Limb Ischaemia  
Status of Angiogenic Inducers  
Angiogenic Therapies for Tissue Repair & Regeneration  
Select Devices Supporting Therapeutic Angiogenesis  
Angiogenesis in Ischemic Heart  
Factors Influencing Ischemic Angiogenesis  
Angiogenesis and CAD  
Angiogenesis in Wound Healing  
Factors Stimulating Wound Angiogenesis  
Factors Impairing Wound Angiogenesis  
Angiogenic Therapy Vs. Conventional Therapy  
Types of Angiogenesis  
Excessive Angiogenesis  
Insufficient Angiogenesis  
Tumor Angiogenesis  
Sequence of Actions

Angiogenesis and Tumor Progression  
Oncogenes vis-à-vis Potential Pro-angiogenic Activities on Tumor Angiogenesis  
Role of Angiogenesis in Skin Diseases  
Select Drugs & Their Targeted Application  
Analysis of Developmental Activities Between Decades  
Role of Enzymes and Inflammatory Cells in Angiogenesis  
Angiogenic Imbalance Augments Retinal Neovascularization  
Oncogenes & VE –cadherin – A Facilitating Role

## **7.PRODUCT APPROVALS AND LAUNCHES**

FDA Withdraws Approval of AstraZeneca's NDA for IRESSA (gefitinib) Tablets  
Pfizer Obtains European Approval for SUTENT® to Treat Pancreatic NET  
Novartis Obtains FDA Approval of New Indication for Afinitor  
FDA Approves Herceptin for Treating Metastatic Adenocarcinoma  
Roche Introduces Avastin in China  
Pfizer Japan Receives Clearance for Torisel in Japan  
GSK Obtains European Commission's Conditional Marketing Approval for Votrient  
FDA Approves Tarceva® for Maintenance Treatment of NSCLC  
FDA Approves GlaxoSmithKline's Votrient  
European Commission Grants Clearance to Torisel for Mantle Cell Lymphoma  
Genetech Receives FDA Approval for Avastin in Renal Cell Carcinoma  
FDA Approves Bevacizumab as Second Line Treatment for Glioblastoma  
Novartis Obtains FDA Approval of Afinitor for Treating Renal Cell Cancer

## **8.PRODUCT APPROVALS AND LAUNCHES – A HISTORIC PERSPECTIVE BUILDER**

FDA Grants Clearance for Gleevec in Treatment of Gastrointestinal Stromal Tumor  
Celgene's Thalidomide Pharmion™ Receives EC Clearance for Treating Multiple Myeloma  
Genentech Obtains FDA Approval for Avastin in Breast Cancer  
FDA Approves Nexavar for Treatment of Hepatocellular Carcinoma  
Wyeth Receives EC Clearance for TORISEL in Advanced Renal Cell Carcinoma  
OSI and Roche Announce Approval of Tarceva® in Japan  
ImClone Obtains FDA Label Expansion for Erbitux®, as Third Line Therapy in mCRC  
REVLIMID® Obtains Swissmedic Authorization in Switzerland  
REVLIMID® Receives Marketing Approval in European Union  
Wyeth Obtains FDA Clearance for Marketing Torisel



Chugai Obtains Approval for Avastin in Japan  
Pfizer Obtains FDA Approval for Sunitinib in Metastatic Renal Cell Carcinoma  
FDA Approves Herceptin in HER2-Overexpressing Breast Cancer Treatment  
Genentech Receives FDA Approval for Bevacizumab in Non-Small Cell Lung Cancer  
Amgen Obtains FDA Approval for Vectibix Treating mCRC  
FDA Grants Marketing Approval for Lucentis in Wet AMD  
Celgene Obtains FDA Clearance for Revlimid in Multiple Myeloma  
FDA Approves Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer  
Celgene Obtains FDA's Accelerated Approval for THALOMID  
Celgene Obtains sNDA Approval for THALOMID from FDA  
ImClone Obtains FDA Clearance for Erbitux® in the treatment of SCCHN  
Pfizer's Sutent Receives FDA Nod for Treatment of Gastrointestinal Stromal Tumor  
Celgene Receives FDA's Subpart H Approval for Revlimid in Myelodysplastic Syndromes  
US FDA Approves OSI's Tarceva® for Treating Pancreatic Carcinoma

## **9.RECENT INDUSTRY ACTIVITY**

Valeant to Take Over Eyetech  
Teva Acquires Cephalo  
Genentech to Carry Out Additional Trial of Avastin in Her2-negative mBC  
Pfizer to Seek regulatory Clearance for Axitinib in Europe and US  
FDA to Withdraw Avastin's Approval for Breast Cancer  
Eyetech Receives QTDP Grant To Develop Extended- Release Formulation of Macugen®  
sanofi-aventis and Regeneron to Continue VELOUR Trial as Planned  
EntreMed Enters into Financing Deal for ENMD-2076 Development  
Chugai Pharmaceuticals Fulfills Condition for Avastin's Approval  
Gilead Sciences to Take Over CGI Pharma  
Mersana Commences XMT-1107 Phase I Clinical Trial  
Astellas Pharma Acquires OSI Pharmaceuticals  
Roche to Conduct a Trial on Anti-Cancer Antibody TB-403  
Mersana Therapeutics Inks License Agreement With Teva  
Accelaron Publishes Pre-clinical Data Study on ACE-041  
Antisense Raises Capital to Continue Phase III Trabedersen Trial  
GSK Receives Positive Opinions from EMEA for Two Cancer Medicines  
EMEA Issues Positive Opinion on GSK's Votrient  
EMEA Issues Positive Opinion on GSK's Anti Cancer Drug Candidate, Tyverb



Abbott Enters into Licensing Agreement with Pierre Fabre  
Arno Therapeutics Inks Global Licensing Agreement with OSU  
BI Initiates Late Stage Clinical Trials for Two Oncology Drug Candidates  
AnGes Obtains US FDA Approval for Phase III Trial of Collatogene™  
Silence Therapeutics and Intradigm Merge  
Mersana Launches First Phase of XMT-1107 Clinical Trial  
ImClone Receives Complete Response Letter for Erbitux® sBLA From FDA  
Oxigene Releases Encouraging Data from OXi4503 Pre-clinical Studies  
Potentia Enters into Licensing and Purchase Option Deal with Alcon  
Quark Receives Additional Patents for RTP 801 Gene Targeting Compounds  
Simcere Enters into Collaboration Deal with OSI Pharmaceuticals  
Pfizer Acquires Wyeth in Cash & Stock Merger  
Gene Signal Releases Interim Results from Phase II Study on GS-101  
Onco to Conduct Second Phase Trial of Fuso's OTS102  
Green Cross Obtains US FDA Approval for Greenstatin Clinical Trial  
OXIGENE Acquire Symphony ViDA  
Roche Releases Positive Results from Phase III Trial of Lucentis  
Pfizer Halts Phase III Sutent Study for Colorectal Cancer  
Morphotek Obtains FDA Clearance for MORAb-004 IND Application  
GlaxoSmithKline Files MAA for Pazopanib in EU  
Roche Acquires Genentech  
Fuso Commences Phase II/III Clinical Trail for OTS102

## **10. STRATEGIC CORPORATE DEVELOPMENTS – A HISTORIC PERSPECTIVE BUILDER**

EntreMed to Funnel Resources on ENMD-2076 Development  
OmegaGenesis Enters Into Collaboration with Mayo Clinic for Angiogenesis Research  
Eli Lilly Acquires ImClone Systems  
EntreMed Demonstrates Antitumor Effects of ENMD-2076  
EntreMed Collaborates with JSB for ENMD-2076 Business Development  
Circadian Technologies Limited Acquires Vegenics  
Fuso and OTS to Initiate Phase II Trial for OTS102  
EntreMed Releases Pre-Clinical Findings of ENMD-2076 in Multiple Myeloma  
Merck Serono Inks Development and Licensing Agreement with Bionomics  
Roche Inks Licensing Agreement with ThromboGenics and BioInvent for TB-403  
Aida Initiates Pre-Clinical Development of New Anti-Cancer Drug  
Cyclacel Pharmaceuticals Releases Pre-Clinical Data of CYC116  
Astellas and CoMentis Ink Agreement to Develop and Commercialize Beta- Secretase

## Inhibitors

Kringle Pharma's NK4 Receives Patent Approval in Japan

UCB Releases Phase II Results of CDP791 in NSCLC Treatment

Celgene Takes Over Pharmion

REVLIMID® Obtains Orphan Drug Designation in Japan

TRACON Commences Phase I Clinical Trial on TRC105

Ark Therapeutics to Acquire Lymphatix

Access Takes Over Somanta

Pfizer Takes Over CovX

Callisto Restructures Licensing Agreement with Genzyme for Atiprimod

EntreMed Receives FDA Approval for ENMD-2076 IND Application

EC Grants Orphan Medicinal Status to REVLIMID for Treatment of CLC

Bristol-Myers Squibb Snaps Up Adnexus Therapeutics

Morvus Takes Over Two Companies

Merck Inks Agreement with BMS and ImClone for Erbitux® Development And Commercialization

FDA Issues a Safety Labeling Update for Bevacizumab Drug

Fuso Initiates Phase I Clinical Study for OST102 Angiogenesis Inhibitor

CRC to Support Bionomics in BN069 Development

Peregrine Secures Licensing Rights for B2GP1 Angiogenesis Inhibitor

AnGes's Angiogenesis-Stimulating Drug Meets Primary End-Point in Phase III Study

ImClone Annuls Development Agreement with UCB

ArQule Partners with Kyowa Hakko in Cancer Compound

Samaritan Snaps Up Metastatin Pharmaceuticals

EU Approves €2 Million Grants for VASOPLUS Consortium

MGH Cancer Center Reports Results of AZD2171 Phase II Trial

AVEO Inks Exclusive Licensing Agreement with Kirin for Novel Anti-Cancer Compound

Sangamo and Edwards Ink Angiogenesis Asset Purchase Agreement

Covalon Secures Perfusion's Gene Therapy Solutions

Vical Strengthens Angiogenesis and Poloxamers IPR Portfolio

Biomira Takes Over ProIX Pharmaceuticals

FDA Gives Out Warning on Bevacizumab Drug

Athenagen Merges with Zapaq

Tigris Secures Global Licensing Rights to Develop and Commercialize New Cancer Therapies

Bayer Yakuhin Files Marketing Application for Nexavar in Japan

Athenagen Purchases Assets of Osprey Pharmaceutical

Amgen Acquires Abgenix

Genmab Enters Exclusive Licensing Agreement with Bionomics

OSI Pharmaceuticals Acquires Eyetech Pharmaceuticals  
FDA Changes Labeling of Iressa, Limiting Use to NSCLC  
Schering AG and Novartis Signs a Agreement to Commercialize Angiogenesis Inhibitor, PTK787  
Bausch & Lomb Signs an Option Agreement with PTC Therapeutics  
Bausch & Lomb Receives License from Cephalon, Inc  
Pharmacopeia Signs a Licensing Agreement with Allergan  
Xantos Biomedicine and Cryptome Enters into Licensing Agreement  
EntreMed Receives US Patent

## **11.FOCUS ON SELECT GLOBAL PLAYERS**

Abbott Laboratories (USA)  
Adnexus Therapeutics, Inc. (USA)  
Æterna Zentaris Inc. (Canada)  
Amgen, Inc. (USA)  
Angstrom Pharmaceuticals Inc. (USA)  
AstraZeneca Plc. (UK)  
Bayer HealthCare AG (Germany)  
Callisto Pharmaceuticals, Inc. (USA)  
Celgene Corporation (USA)  
Celltech Group Plc. (UK)  
Cephalon Inc. (USA)  
Eisai Inc. (USA)  
Eli Lilly And Company (USA)  
ImClone Systems Inc. (USA)  
EntreMed Inc. (USA)  
GenVec Inc. (USA)  
Genzyme Corp. (USA)  
GlaxoSmithKline Plc (UK)  
Merck KGaA (Germany)  
Novartis (Switzerland)  
OSI Pharmaceuticals, Inc. (USA)  
Eyetech, Inc. (USA)  
Pfizer Inc. (USA)  
Progen Industries (Australia)  
Regeneron Pharmaceuticals  
Roche (Switzerland)  
Genentech Inc. (USA)

Chugai Pharmaceutical Co. Ltd. (Japan)  
Silence Therapeutics  
ThromboGenics Limited (Ireland)

## 12. GLOBAL MARKET PERSPECTIVE

**Table 5.** World Recent Past, Current & Future Analysis for Angiogenesis Inhibitors & Stimulators by Geographic Region/Country – US, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US\$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart)

**Table 6.** World Historic Review for Angiogenesis Inhibitors & Stimulators by Geographic Region/Country – US, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 7.** World 15-Year Perspective for Angiogenesis Inhibitors & Stimulators by Geographic Region/Country – Percentage Breakdown of Dollar Sales for US, Europe and Rest of World Markets for Years 2003, 2011 and 2017 (includes corresponding Graph/Chart)

**Table 8.** World Recent Past, Current & Future Analysis for Angiogenesis Inhibitors by Geographic Region/Country – US, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US\$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 9.** World Historic Review for Angiogenesis Inhibitors by Geographic Region / Country – US, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 10.** World 15-Year Perspective for Angiogenesis Inhibitors by Geographic Region/Country – Percentage Breakdown of Dollar Sales for US, Europe and Rest of World Markets for Years 2003, 2011 and 2017 (includes corresponding Graph/Chart)

**Table 11.** World Recent Past, Current & Future Analysis for Angiogenesis Stimulators by Geographic Region/Country – US, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US\$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 12.** World Historic Review for Angiogenesis Stimulators by Geographic Region / Country – US, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 13.** World 15-Year Perspective for Angiogenesis Stimulators by Geographic Region/Country – Percentage Breakdown of Dollar Sales for US, Europe and Rest of World Markets for Years 2003, 2011 and 2017 (includes corresponding Graph/Chart)

### **III. MARKET**

#### **1. THE UNITED STATES**

##### A. Market Analysis

Angiogenic Inhibitors

List of FDA Approved Anti-Angiogenic Drugs

Pipeline Status By Disease

Anti-Angiogenesis Therapeutics In Phase III Development for Renal Cell Carcinoma: As of 2010

Anti-Angiogenesis Therapeutics In Phase III Development for Breast Cancer Treatment: As of 2010

Angiogenesis Stimulators

Historical Market Snapshots

Market Influencers

Types of Drug Approvals

New Drug Approval (NDA)

Orphan Drug Act

Benefits Derived on Successful Grant of Orphan Drug Status

Angiogenesis Foundation

Key Role of the Foundation in Angiogenesis

The Rising Concern

Cancer

Cancer Statistics in US

A Picture of Colon Cancer in the US

Pancreatic Cancer

Vital Statistics

**Table 14.** New Cancer Cases in the US By Affected Site: 2009

**Table 15.** New Cancer Cases in Males in US by Leading Site: 2009 (includes corresponding Graph/Chart)

**Table 16.** New Cancer Cases in Females in US by Leading Site:2009 (includes corresponding Graph/Chart)

**Table 17.** Cancer Related Deaths in the US By Affected Site:2009

**Table 18.** Cancer Related Deaths in Males in US by Leading Site: 2009 (includes corresponding Graph/Chart)

**Table 19.** Cancer Related Deaths in Females in US by Leading Site: 2009 (includes corresponding Graph/Chart)

AMD and DME Incidence in the US

Rheumatoid Arthritis: Another Emerging Threat

Diabetic Retinopathy

Coronary Artery Disease (CAD)

Myocardial Infarction Statistics in the US

Peripheral Arterial Disease

B. Market Analytics

**Table 20.** The US Recent Past, Current & Future Analysis for Angiogenesis Inhibitors & Stimulators by Product Segments–Angiogenesis Inhibitors and Angiogenesis Stimulators Markets Independently Analyzed with Annual Sales in US\$ Million for Years 2009 through 2015 (includes corresponding Graph/Chart)

**Table 21.** The US Historic Review for Angiogenesis Inhibitors & Stimulators by Product Segments– Angiogenesis Inhibitors and Angiogenesis Stimulators Markets Independently Analyzed with Annual Sales in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 22.** The US 15-Year Perspective for Angiogenesis Inhibitors & Stimulators by Product Segments – Percentage Breakdown of Dollar Sales for Angiogenesis Inhibitors & Stimulators for Years 2003, 2011 and 2017 (includes corresponding Graph/Chart)

## **2.EUROPE**

## A. Market Analysis

### Angiogenesis Market – A Historic Perspective

#### Cancer Trends

**Table 23.** Cancer Incidence in Europe by Site (2009) (includes corresponding Graph/Chart)

## B. Market Analytics

**Table 24.** European Recent Past, Current & Future Analysis for Angiogenesis Inhibitors & Stimulators by Product Segments—Angiogenesis Inhibitors and Angiogenesis Stimulators Markets Independently Analyzed with Annual Sales in US\$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 25.** European Historic Review for Angiogenesis Inhibitors & Stimulators by Product Segments— Angiogenesis Inhibitors and Angiogenesis Stimulators Markets Independently Analyzed with Annual Sales in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 26.** European 15-Year Perspective for Angiogenesis Inhibitors & Stimulators by Product Segments – Percentage Breakdown of Dollar Sales for Angiogenesis Inhibitors & Stimulators for Years 2003, 2011 and 2017 (includes corresponding Graph/Chart)

## 3.REST OF WORLD

### A. Market Analysis

#### Japanese Market

#### Quest for New Opportunities

### B. Market Analytics

**Table 27.** Rest of World Recent Past, Current & Future Analysis for Angiogenesis Inhibitors & Stimulators by Product Segments—Angiogenesis Inhibitors and Angiogenesis Stimulators Markets Independently Analyzed with Annual Sales in US\$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 28.** Rest of World Historic Review for Angiogenesis Inhibitors & Stimulators by



Product Segments– Angiogenesis Inhibitors and Angiogenesis Stimulators Markets Independently Analyzed with Annual Sales in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 29.** Rest of World 15-Year Perspective for Angiogenesis Inhibitors & Stimulators by Product Segments – Percentage Breakdown of Dollar Sales for Angiogenesis Inhibitors & Stimulators for Years 2003, 2011 and 2017 (includes corresponding Graph/Chart)

#### **IV. COMPETITIVE LANDSCAPE**

Total Companies Profiled: 69 (including Divisions/Subsidiaries - 85)

The United States (50)

Canada (2)

Japan (3)

Europe (22)

- France (2)

- Germany (5)

- The United Kingdom (6)

- Italy (3)

- Rest of Europe (6)

Asia-Pacific (Excluding Japan) (8)

## I would like to order

Product name: Angiogenesis Inhibitors and Stimulators: Market Research Report

Product link: <https://marketpublishers.com/r/A874EE8DE26EN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A874EE8DE26EN.html>